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NF-jB Inhibition through Proteasome Inhibition or
IKKb Blockade Increases the Susceptibility of
Melanoma Cells to Cytostatic Treatment through
Distinct Pathways
Katharina Amschler1,2,3,5, Michael P. Scho¨n1,2,3,5, Nadin Pletz1, Katrin Wallbrecht1, Luise Erpenbeck1 and
Margarete Scho¨n4
Metastasized melanoma is almost universally resistant to chemotherapy. Given that constitutive or drug-
induced upregulation of NF-kB activity is associated with this chemoresistance, NF-kB inhibition may increase
the susceptibility to antitumoral therapy. On the cellular level, two principles of NF-kB inhibition, proteasome
inhibition by bortezomib and IkB kinase-b (IKKb) inhibition by the kinase inhibitor of NF-kB-1 (KINK-1),
significantly increased the antitumoral efficacy of camptothecin. When combined with camptothecin, either of
the two NF-kB-inhibiting principles synergistically influenced progression-related in vitro functions, including
cell growth, apoptosis, and invasion through an artificial basement membrane. In addition, when C57BL/6 mice
were intravenously injected with B16F10 melanoma cells, the combination of cytostatic treatment with either of
the NF-kB-inhibiting compounds revealed significantly reduced pulmonary metastasis compared to either
treatment alone. However, on the molecular level, nuclear translocation of p65, cell cycle analysis, and
expression of NF-kB-dependent gene products disclosed distinctly different molecular mechanisms, resulting
in the same functional effect. That proteasome inhibition and IKKb inhibition affect distinct molecular pathways
downstream of NF-kB, both leading to increased chemosensitivity, is previously unreported. Thus, it is
conceivable that switching the two principles of NF-kB inhibition, once resistance to one of the agents occurs,
will improve future treatment regimens.
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INTRODUCTION
One of the central challenges of today’s cancer management
is intrinsic or acquired resistance of advanced tumors to
antitumoral therapy (Wang et al., 1999; Nakanishi and Toi,
2005). Melanoma, an aggressive skin cancer with the highest
mortality of all skin diseases, vividly highlights this problem,
as it is almost universally resistant to chemotherapy.
Response rates to dacarbazine, the only agent approved by
the Food and Drug Administration (FDA) for the treatment of
metastatic melanoma, rarely exceed 5–10% (Helmbach et al.,
2001; Soengas and Lowe, 2003). In addition, numerous
phase-III clinical trials, including antitumoral vaccination
with or without dendritic cells, antibody- or cytokine-based
immunotherapy, radiation, and chemotherapy, have yielded
largely sobering results (Grossman et al., 2001; Lens, 2008). It
is thought that melanoma cells have acquired several
mutually enhancing mechanisms, such as multidrug elimina-
tion or apoptosis deficiency, which lead to resistance against
virtually all of the currently available therapeutic approaches
(Grossman and Altieri, 2001; Soengas and Lowe, 2003).
Strategies employed by malignant tumors to evade
antitumoral therapies include upregulation of the central
transcription factor NF-kB that, among its function as a
pivotal regulator of many cellular functions, contributes to
aggressive growth and chemoresistance of some tumors (Kim
et al., 2006; Ueda and Richmond, 2006). The NF-kB family
comprises five members: p50/p105 (NF-kB1), p52/p100
(NF-kB2), c-Rel, RelB, and p65 (RelA). Each of these protein
subunits possesses a Rel-homology domain that is involved in
DNA binding, dimerization, and interaction with IkB proteins
(Karin and Lin, 2002; Kumar et al., 2004; Perkins, 2007). In
normal cells, NF-kB is retained in the cytoplasm through
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Stimulation of the IkB kinase (IKK) complex, for example,
by tumor necrosis factor-a, lipopolysaccharide, IL-1, or other
stimuli, leads to phosphorylation of IkB and, consecutively,
release of NF-kB (Karin et al., 2004). The latter can then
translocate into the nucleus and initiate the transcription of
cancer progression-relevant proteins such cytokines, chemo-
kines, cyclin D1, matrix metalloproteinases, and antiapopto-
tic proteins (Baldwin, 2001; Yang and Richmond, 2001;
Karin et al., 2004; Karin, 2006). Upregulation of these
proteins could mediate, at least in part, resistance to
antitumoral treatments. In addition, some cytostatic com-
pounds including doxorubicin (and other anthracycline
drugs) or camptothecin activate NF-kB, thus presumably
contributing themselves to chemoresistance of some cancer
cells (Huang et al., 2000). Therefore, the combinatorial
treatment of tumors using NF-kB inhibition and chemother-
apy is an intensively studied principle that has been tested in
hematological malignancies and also in solid tumors such as
colon cancer and melanoma (Arlt et al., 2003; Amiri et al.,
2004; Fukuyama et al., 2007; Scho¨n et al., 2008).
In fact, the proteasome inhibitor bortezomib, whose
predominant biological effect is inhibition of NF-kB activa-
tion and, consecutively, downmodulation of NF-kB-depen-
dent gene products, has been approved for the treatment of
multiple myeloma and mantle cell lymphoma (Denz et al.,
2006). However, bortezomib exerts a number of off-target
effects, thus showing a somewhat pleiotropic mode of action
(Ciechanover and Schwartz, 1998; Paramore and Frantz,
2003; Chauhan et al., 2005; Ludwig et al., 2005; Nencioni
et al., 2006). Kinase inhibitor of NF-kB-1 (KINK-1) is a
recently described highly selective small-molecule inhibitor
of IKKb (Scho¨n et al., 2008).
We provide here to our knowledge previously unreported
evidence for distinctly different molecular changes induced
by either of the two NF-kB-inhibiting principles, both
eventually resulting in similar effects on the cellular level,
namely, the desired enhanced susceptibility of melanoma
cells to antitumoral treatment. It is, therefore, conceivable
that switching and/or combining different NF-kB-inhibiting
agents in the course of therapy will keep tumor cells
susceptible to antitumoral treatments.
RESULTS
Differential activation of NF-jB and expression of
NF-jB-regulated gene products in melanoma cell lines
Constitutive activation of NF-kB has been described as a
hallmark feature in several tumors, including prostate cancer,
breast cancer, multiple myeloma, pancreatic cancer, and
melanoma (Davis et al., 2001; Yang and Richmond, 2001;
Liptay et al., 2003). In contrast to normal melanocytes, many
melanoma cells show constitutive activation of NF-kB (Amiri
and Richmond, 2005). However, given that expression and
activation of NF-kB in these tumors may vary widely, we first
analyzed NF-kB activation in eight different melanoma lines.
As shown by electrophoretic mobility shift assays (which
detect activated NF-kB within the nuclear fraction of the
cells), the lines MMNH, MV3, and MeWo showed the highest
constitutive NF-kB activity, whereas Brown, Lox, and A375
showed intermediate levels, and Mel-2a showed the lowest
signal intensity (Figure 1a). Activation of NF-kB results in
constitutive transcription and expression of several NF-kB-
dependent gene products in melanoma cells (Scho¨n et al.,
2008). When eight melanoma cell lines were exposed to
tumor necrosis factor-a, a treatment that induces profound
activation of NF-kB through stimulation of the IKK complex,
phosphorylation of IkB, and consecutive release of NF-kB, a
marked enhancement of NF-kB was seen in the cell lines
MeWo, MMNH, and MV3. The cell lines Brown, A375, and
Lox showed moderate induction of NF-kB activity, and the
lines SK-Mel-23 and Mel-2a did not respond detectably to
incubation with tumor necrosis factor-a (Figure 1a). As shown
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Figure 1. Differential activation of NF-jB and heterogeneous expression of
NF-jB-dependent proteins in melanoma cells. (a) Constitutive NF-kB
activation was assessed in six melanoma lines. Cells were lysed, nuclear
extracts were prepared, and activated NF-kB was determined by
electrophoretic mobility shift assays (EMSA) as outlined in Materials and
Methods. The panel depicts an additional control lane (A375-cold) in which
the specific signal was abrogated by unlabeled (cold) oligonucleotides to
show specificity. (b) Tumor necrosis factor-a (TNFa)-stimulated NF-kB
activation in eight melanoma lines. (c) Nuclear extracts of A375 melanoma
cells were incubated with antibodies directed against p65, p50, or a
combination of both for 30minutes. Thereafter, NF-kB was determined by
EMSA showing that probes containing p65 shifted the signal of the upper band
to higher molecular weight. (d) Expression of the NF-kB-dependent proteins,
c-MYC and cyclin D1, was detected by western blot analysis in the nuclear
extracts; survivin and X-linked inhibitor of apoptosis protein (XIAP) were
detected in cytosolic extracts. The lower panel shows the housekeeping
protein b-actin.
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by supershift assays (performed to detect specific NF-kB
subunits within the nuclear extracts), the detected bands
contained the p65 subunit (Figure 1b depicts the melanoma
line A375 as an example).
In the next series of experiments, we analyzed the eight
melanoma lines regarding expression of several gene
products whose regulation is known to depend on NF-kB
and which are involved in tumor progression-relevant
cellular functions, such as proliferation or apoptosis. Proteins
investigated in these experiments included c-MYC and cyclin
D1, both regulators of the cell cycle, as well as X-linked
inhibitor of apoptosis protein (XIAP) and survivin, two
inhibitors of apoptosis. Again, the expression of these proteins
showed considerable variability between the melanoma
lines, and apparently the expression levels did not correlate
with the levels of constitutive NF-kB activation in the
respective melanoma lines (Figure 1c). Thus, the molecular
heterogeneity of the melanoma lines tested suggested that it is
not trivial to define common mechanisms that may explain
the role of constitutive NF-kB activation for the malignant
potential of a given tumor cell.
Bortezomib and KINK-1 diminish NF-jB activity, but
differentially affect NF-jB-dependent gene products
On the basis of its medium levels of constitutive NF-kB
activation, inducibility of NF-kB activation, and average
expression of several NF-kB-dependent gene products, the
cell line A375 was primarily selected for further functional
studies regarding the effects of NF-kB-inhibiting compounds
in vitro. Most key findings were then confirmed with two
other melanoma lines with similar characteristics, MMNH
and MV3. Non-toxic doses (that is, doses which did not
induce apoptosis or inhibition of cell proliferation) of KINK-1
and bortezomib were determined in a large series of
dose–response experiments (data not shown). KINK-1 is a
specific small-molecule inhibitor of IKKb phosphorylation, an
activity that was shown in three melanoma lines, MMNH,
A375, and Mel-2a (Scho¨n et al., 2008). Given that recent
reports suggested that bortezomib may actually upregulate
NF-kB in some cancer cells (for example, endometrial
carcinoma (Dolcet et al., 2006)), we had to exclude first that
NF-kB inhibitors exerted a similar ‘‘paradoxical’’ effect in
melanoma cells. Therefore, the next series of experiments
was designed to test the effect of both bortezomib and
KINK-1 on NF-kB activity in melanoma cells. Electrophoretic
mobility shift assays showed that the activity of NF-kB was
decreased by both KINK-1 and bortezomib. While KINK-1
inhibited NF-kB activation in a clearly concentration-
dependent manner (Figure 2a), bortezomib achieved rapid
downregulation at high concentrations of X10 ngml1
(Figure 2b).
When NF-kB-regulated gene products implicated in tumor
progression (Denkert et al., 2001; Dhawan and Richmond,
2002; Payne and Cornelius, 2002; Eck et al., 2003;
Gazzaniga et al., 2007) were studied under the influence of
bortezomib or KINK-1, a clear-cut downregulation of the
chemokines CXCL8 (IL-8), CXCL1 (Gro-a), and CCL1 (mono-
cyte chemotactic protein-1 (MCP-1)) was found (Figure 3a).
As shown by quantitative real-time PCR, this concentration-
dependent downregulation of CXCL1 and CXCL8 was some-
what more pronounced when the melanoma cells were
incubated with KINK-1 as compared with bortezomib.
Although the concentration-dependent diminution of CCL1
(MCP-1) and CXCL8 (IL-8) correlated with diminished
nuclear translocation of p65 (Figure 2), COX-2 (cycloox-
ygenase-2) expression appeared to increase again with higher
KINK-1 concentrations (Figure 3a).
Some proteins involved in the regulation of apoptosis
and/or cell proliferation (Levine, 1997; Oda et al., 2000;
Fernandez et al., 2005) responded differentially when
melanoma cells were exposed to bortezomib or KINK-1;
although bortezomib induced a strong concentration-depen-
dent upregulation of both NOXA and p53 (by 480 and 270%,
respectively, as determined by densitometric analysis), this
effect was not seen with KINK-1 (Figure 3b). In fact, NOXA
was even downregulated by KINK-1 (by 40%). In contrast,
bortezomib induced downregulation of cyclin D1 (by 50%)
and, at high concentrations of 30 ngml1, led to decreased
expression of survivin. The reduction of cyclin D1 was less
pronounced when the cells were exposed to KINK-1, and
expression of survivin was not affected by KINK-1. Expression
of Bcl-XL and the ratio of Bcl-2/Bax were not appreciably
affected by either of the two compounds (Figure 3b).
Overall, bortezomib and KINK-1, both at concentrations
sufficient to inhibit NF-kB activation, induced differential
responses of some NF-kB-dependent gene products impli-
cated in tumor progression, thus suggesting differences in
their mode of action on the molecular level.
Differential cell cycle modulation in melanoma cells by
bortezomib and KINK-1
Given that the expression of proteins involved in cell cycle
regulation, such as cyclin D1 and p53, were differentially
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Figure 2. Bortezomib and kinase inhibitor of NF-jB-1 (KINK-1) inhibit
activation and nuclear translocation of NF-jB. (a) Nuclear extracts were
prepared from melanoma cells (cell line A375), which had been incubated
with KINK-1 at the indicated concentrations for 18 hours. At 1 hour before
harvesting, the medium was replaced by new medium containing tumor
necrosis factor-a (TNFa) (1 nM) to stimulate activation and nuclear
translocation of NF-kB. (b) NF-kB was detected by electrophoretic mobility
shift assay in extracts from cells treated with bortezomib at the indicated
concentrations for 18 hours. Again, activation and nuclear translocation of
NF-kB was stimulated by TNFa (1 nM) 1 hour before harvesting.
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influenced by bortezomib and KINK-1, it was conceivable
that the two compounds exerted divergent effects on the
mitotic cycle of melanoma cells. To test this hypothesis,
melanoma cells were exposed to KINK-1 (5 or 15 mM for 4 or
12 hours, respectively) or bortezomib (5 or 10 ngml1 for 4 or
12 hours, respectively) after thymidine treatment, a method
that leads to an initial G1/S-phase arrest and subsequent
‘‘synchronization’’ of the cells. At 4 hours after being
‘‘released’’ by addition of fresh culture medium, all melano-
ma cell populations were predominantly in the G1/S-phase
corresponding to the expected synchronizing effect of
thymidine (Figure 4). However, remarkable differential effects
of the two compounds became apparent after 12 hours: the
majority of A375 cells treated with 5 mM KINK-1 reentered the
mitotic cycle, and even in the population exposed to 15 mM
KINK-1, only 56% of the cells were arrested in the G2/S-
phase. In contrast, even low-dose treatment with bortezomib
(5 ngml1) led to long-lasting arrest of most cells (86%) in the
G2/S-phase. Increasing the concentration of bortezomib to
10 ngml1 did not further enhance this effect (Figure 4). Thus,
KINK-1 and bortezomib clearly showed differential effects on
the cell cycle of melanoma cells.
Differential synergistic effects of KINK-1 and bortezomib with
antitumoral treatment
To test the effect of the two NF-kB inhibitors on melanoma
cells in the context of chemotherapeutic treatment, either
of the two compounds (KINK-1 (5 mM), or bortezomib
(5 ngml1)) was combined with camptothecin (0.03 mM, that
is, a concentration that did not cause tumor cell apoptosis, as
determined in dose–response experiments; data not shown).
Both semiquantitative reverse transcription-PCR and quanti-
tative real-time PCR (Figure 5a and b) determining several
tumor progression-related gene products revealed some
remarkable differences between the two NF-kB inhibitors:
the camptothecin-induced chemokines, CXCL1 (Gro-a) and
CXCL8 (IL-8), could both be repressed by KINK-1, whereas
co-treatment with bortezomib did not reduce this activation
(Figure 5a and b). In addition, CCL1 (MCP-1) was down-
regulated by combinatorial treatment with camptothecin
and KINK-1, but not with camptothecin and bortezomib
(Figure 5a). In contrast, both the cdk inhibitor p21 and
COX-2 were upregulated by camptothecin, but neither
KINK-1 nor bortezomib antagonized this effect at non-toxic
doses (Figure 5a).
When the induction of apoptosis in melanoma cells was
studied, it was found that camptothecin-induced upregula-
tion of the Bcl-2 family protein NOXA was markedly
augmented by bortezomib, whereas KINK-1 achieved a less
pronounced increase (Figure 5c). The ratio of Bcl-2 and Bax,
an antiapoptotic and a pro-apoptotic protein of the Bcl-2
family (Figure 5c), or the expression of the inhibitors of
apoptosis, XIAP and survivin (data not shown), were not
detectably altered when suboptimal (that is, non-toxic)
concentrations of camptothecin were combined with either
KINK-1 or bortezomib. However, camptothecin stimulated
the release of mitochondrial cytochrome C (a critical step in
the mitochondrial pathway of apoptosis followed by binding
to Apaf-1 and creation of the apoptosome). Bortezomib, but
not KINK-1, led to a marked increase of the camptothecin-
induced release of cytochrome C (Figure 5d).
As determined by the generation of histone-bound DNA
fragments, both KINK-1 and bortezomib led to significantly
increased apoptosis of melanoma cells to B200% when
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Figure 3. Differential response of NF-jB-regulated gene products to
treatment with kinase inhibitor of NF-jB-1 (KINK-1) and bortezomib.
(a) Melanoma cells (cell line A375) were exposed to KINK-1 or bortezomib
at the indicated concentrations for 18 hours and stimulated with 1 nM tumor
necrosis factor-a (TNFa). The upper four panels depict quantitative
real-time PCR of mRNA expression of CXCL8 (IL-8) and CXCL1 (Gro-a).
Values shown are the average of triplicate measurements (±SD), and the
experiments were repeated twice with similar results. The lower panels
depict semiquantitative reverse transcription-PCR results. (b) Melanoma
cells were incubated with KINK-1 or bortezomib at the indicated
concentrations for 18 hours. Several proteins involved in apoptosis and/or
proliferation were detected by western blot analysis of nuclear extracts
(cyclin D1 and p53), cytosolic extracts (X-linked inhibitor of apoptosis
protein (XIAP) and survivin), or whole cell lysates (NOXA, Bcl-XL, Bax,
and Bcl-2) as outlined in Materials and Methods.
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combined with suboptimal concentrations of camptothecin
(0.03 mM; Po0.01 and Po0.05, respectively, as compared
with camptothecin alone; Figure 5e). When camptothecin
was used at higher concentrations (0.10 mM), which were
sufficient to kill melanoma cells, neither KINK-1 nor
bortezomib increased the pro-apoptotic activity (Figure 5e).
Thus, combinatorial treatment with either of the two NF-kB
inhibitors increased the susceptibility of melanoma cells to
treatment with camptothecin, although the molecular me-
chanisms underlying this synergistic effect appeared to differ
between the two compounds.
Camptothecin-induced inhibition of melanoma cell invasion is
potentiated by KINK-1 or bortezomib
Invasion through the extracellular matrix is a crucial step in
tumor progression and NF-kB is a key regulator of gene
products implicated in tumor cell invasion (for example,
COX-2 and matrix metalloproteinase-9 (MMP-9)). On the
basis of this notion, a two-well culture system was used to
assess the invasion of fluorescently labeled melanoma cells
into an artificial extracellular matrix in the presence of
camptothecin, KINK-1, or bortezomib alone, as well as in
the presence of camptothecin combined with KINK-1 or
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Figure 4. Differential effect of kinase inhibitor of NF-jB-1 (KINK-1) and bortezomib on the cell cycle of melanoma cells. Melanoma cells (cell line
A375) were synchronized by thymidine treatment (2mM) before incubation with vehicle, KINK-1 (5 or 15 mM), or bortezomib (5 or 10 ngml1) for 4 hours
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bortezomib. As shown in Figure 6, camptothecin alone
resulted in only moderate inhibition of melanoma cell
invasion, and monotreatment with KINK-1 or bortezomib
did not affect the invasive behavior of the cells. However,
when suboptimal concentrations of camptothecin were
combined with either of the NF-kB inhibitors, melanoma
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cell invasion was dramatically reduced. In particular,
combination of camptothecin and KINK-1 resulted in
complete abrogation of tumor cell invasion, whereas few
invading cells were observed when camptothecin was
combined with bortezomib (Figure 6).
Bortezomib and KINK-1 increase the antitumoral activity of
camptothecin in vivo
To assess the in vivo efficacy of NF-kB inhibitors alone or in
combination with camptothecin, a syngeneic system of
C57BL/6 mice injected intravenously with B16F10 melanoma
cells was used. Preliminary in vitro experiments had
established that the murine melanoma cells showed similar
apoptotic responses, inhibition of invasion, and regulation of
several NF-kB-dependent gene products as the human A375
and MMNH melanoma lines when treated with camptothe-
cin, KINK-1, bortezomib, or a combination thereof (data not
shown). B16F10 melanoma cells (2.5 105 cells per mouse)
were injected into the tail vein of C57BL/6 mice (n¼6 mice
per group, the experiment was performed twice), and
treatment was started 1 day after tumor cell injection. It
had been established in another set of preliminary experi-
ments using green fluorescent protein (GFP)-transfected
B16F10 melanoma cells that intrapulmonary arrest of the
tumor cells had taken place at this time point, thus excluding
the possibility that the treatment interfered with the very early
steps (for example, cell adhesion) of experimental metastasis
(Figure 7a). When pulmonary metastasis in the experimental
animals was evaluated 17 days after melanoma cell injection,
it was found that multiple metastases had formed in the
lungs of control mice as well as in the lungs of mice treated
with either bortezomib (0.5mg kg1 on day 1 and 6, and
0.25mg kg1 on day 11) or KINK-1 (3mg kg1 every other
day; Figure 7b and c). Monotherapy with camptothecin
(1.8mg kg1 every 3 days) resulted in moderate, not
statistically significant reduction of pulmonary metastasis
(Figure 7c). However, when the mice were treated by using a
combination of camptothecin and bortezomib or KINK-1 a
marked synergistic antitumoral response was evident. As
determined by two objective methods, lung weight as a
surrogate parameter for tumor masses (Figure 7c, upper
panel) and computer-based morphometric analysis of metas-
tasis-covered lung surfaces (Figure 7c, bottom panel), the
combination of camptothecin with either of the two NF-kB
inhibitors achieved significantly lower metastasis as com-
pared with either therapy alone or the controls (Po0.01 and
Po0.05, respectively).
To investigate the effects of camptothecin with and
without the NF-kB inhibitors on cellular and molecular level
in vivo, apoptosis in pulmonary melanoma metastases was
assessed by TUNEL assays and apoptotic indices (percentage
of TUNEL-positive cells within the tumor metastases) were
calculated. It was found that monotherapy with either
compound, camptothecin, bortezomib, or KINK-1, did not
induce significant apoptosis in the melanoma metastases
(apoptotic indices between 0.21 and 0.94) compared with
untreated controls (apoptotic index 0.32; Figure 8a and b). In
contrast, when mice were treated with a combination of
camptothecin and bortezomib, the apoptotic index was
12.45 (SD¼3.28; Po0.001 compared with either of the
monotherapies; Figure 8a and b). Likewise, when mice were
treated with a combination of camptothecin and KINK-1, the
apoptotic index was 13.06 (SD¼3.79; Po0.001 compared
with either of the monotherapies; Figure 8a and b).
In metastases of untreated mice or mice treated by
camptothecin monotherapy, nuclear expression of NF-kB
could be detected in some tumor cells by immunohisto-
chemistry. In contrast, such nuclear localization of NF-kB
was not detectable in metastases of mice treated with
bortezomib, KINK-1, or a combination of either of the
NF-kB inhibitors with camptothecin, suggesting that nuclear
NF-kB translocation has been inhibited in vivo (Figure 8c).
Immunohistochemical staining of p53 and NOXA in the
metastases did not reveal clear differences between the
different mouse groups (data not shown).
DISCUSSION
Evidence for the involvement of NF-kB in oncogenesis is not
new (Nakanishi and Toi, 2005). Indeed, many NF-kB-
regulated gene products have been implicated in cellular
transformation, proliferation, inhibition of apoptosis,
invasion, angiogenesis, or metastasis (Karin et al., 2002;
Karin, 2006). On the one hand, many tumor cells, in contrast
to their normal counterparts, show constitutive activation of
NF-kB (Aggarwal, 2004; Kumar et al., 2004; Karin, 2006). On
the other hand, treatment of malignancies with some
cytostatic compounds, such as anthracycline drugs or
camptothecin, leads to induced activation of NF-kB (Huang
et al., 2000; Helmbach et al., 2001; Laurent and Jaffrezou,
2001). The latter mechanism is considered a major cause for
the development of inducible chemoresistance (Liu, 1989;
Wang, 1996; Das and White, 1997; Wang et al., 1999;
Huang et al., 2000; Laurent and Jaffrezou, 2001; Ivanov et al.,
2003). Thus, strategies to inhibit NF-kB in malignant tumors
Figure 5. Kinase inhibitor of NF-jB-1 (KINK-1) and bortezomib enhance the susceptibility of melanoma cells to cytostatic treatment with camptothecin.
Melanoma cells (cell line A375) were incubated with vehicle (DMSO 0.1%, control), KINK-1 (5 mM), bortezomib (borte.) (5 ngml1), camptothecin (campto.)
(0.03mM), or combinations as indicated. (a) Expression of the indicated tumor progression-related NF-kB-regulated gene products was determined by
semiquantitative reverse transcription-PCR. (b) CXCL8 and CXCL1 were assessed by quantitative real-time PCR. Values shown are the average of triplicate
measurements (±SD), and the experiment was repeated twice with similar results. (c) Expression of the indicated apoptosis-related proteins was assessed by
western blot analysis. (d) Cytochrome C (cyto. C) was determined by western blot analysis in the mitochondrial (mito.) and cytoplasmic (cyto.) fractions. The
housekeeping protein b-actin is shown for each lysate. (e) Apoptosis was assessed in each of the cultures by determining the generation of histone-bound DNA
fragments. Values shown are the average of triplicate measurements (±SD), and the experiment was repeated twice with similar results. The indicated P-values
were determined using the two-tailed t-test.
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are considered a worthwhile addition to the current
therapeutic armamentarium. The proteasome–ubiquitin sys-
tem is currently the prime target for several pharmacological
approaches, such as proteasome inhibitors, inhibitors of
E1/E2 enzymes, inhibitors of E3 ubiquitin ligases, inhibitors of
de-ubiquitinylating enzymes, or inhibitors of the protea-
some–ubiquitin substrate surface (Guedat and Colland,
2007). The lead compound of the proteasome inhibitors,
bortezomib, has been used in many clinical trials to treat
various malignancies and is currently approved for the
treatment of multiple myeloma and mantle cell lymphoma
(Paramore and Frantz, 2003; Amiri et al., 2004; Ludwig et al.,
2005; Denz et al., 2006).
Nuclear factor-kB activation by camptothecin, a potent
inhibitor of topoisomerase I that impairs DNA replication,
RNA transcription, and DNA damage repair, involves
degradation of IkB and depends on the presence of IKKb,
which are the two principles targeted in our study (Huang
et al., 2000). The efficacy of camptothecin in murine
melanoma models has been shown previously (Liu, 1989;
Dora et al., 2006). In our experimental setting, NF-kB
inhibition, either through proteasome inhibition by bortezo-
mib (Huang et al., 2000) or through IKKb inhibition by the
novel selective inhibitor KINK-1 (Scho¨n et al., 2008), led to
significant synergistic enhancement of the antitumoral
activity of camptothecin. When suboptimal concentrations
of camptothecin were combined with either of the com-
pounds, significant synergistic effects were observed regard-
ing in vitro induction of melanoma cell apoptosis and
suppression of invasion, as well as inhibition of in vivo
metastasis in a murine model. However, the molecular mode
of action of the two NF-kB inhibitors appeared to be
conspicuously different. Although both strategies, IKKb
inhibition by KINK-1 and proteasome inhibition by bortezo-
mib, showed the expected decrease of NF-kB activity, it is
noteworthy that distinctly different regulations of some
NF-kB-dependent gene products were observed (schemati-
cally depicted in Figure 9). Several hypotheses, which are not
mutually exclusive, can be delineated to explain these
observations at least in part.
First, proteasome inhibitors, such as bortezomib, may
exert pleiotropic and/or off-target effects (Adams, 2004). Such
effects include the dramatic upregulation of the pro-apoptotic
protein NOXA, a salient feature of several proteasome
inhibitors, as well as upregulation of p53, which were
not seen with the IKKb inhibitor, KINK-1. These effects are,
at least in part, independent of proteasome inhibition or
NF-kB inhibition (Nikiforov et al., 2007). The net result
would be that some gene products, which are not affected by
more specific NF-kB inhibitors, are influenced by bortezo-
mib. It is conceivable, of course, that KINK-1 also exerts
off-target effects, but such an activity has not been shown yet,
and it may be different from the effects exerted by
bortezomib.
Second, the proteasome controls a plethora of survival
factors in mammalian cells and it is involved in the
degradation of all poly-ubiquitinylated proteins. Therefore,
proteasome inhibition does not only lead to reduced
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Figure 6. Inhibition of melanoma cell invasion by camptothecin is synergistically
enhanced by kinase inhibitor of NF-jB-1 (KINK-1) or bortezomib. (a) Melanoma
cells (cell line A375) were treated with the indicated concentrations of
KINK-1, bortezomib, and camptothecin alone or in combination for 16 hours.
The cells were then seeded into wells containing an artificial basement
membrane and were allowed to invade this matrix for 24 hours. Fluorescent
labeling of the cells was performed as outlined in Materials and Methods.
The photomicrographs depict representative areas of each of the cultures.
The cultures shown are representative of three independent experiments
showing similar results. Bar¼20mm (b) Quantitative analysis of three independent
experiments. **Indicates P¼ 0.00057 for combinatorial treatment with
camptothecin and bortezomib and P¼0.00036 for combinatorial treatment with
camptothecin and KINK-1, respectively, as compared with the untreated control.
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degradation of IkB and, consecutively, reduced activity of
NF-kB but also to alterations in a variety of other signaling
molecules (Orlowski and Kuhn, 2008). It appears, therefore,
that the proteasome inhibitor, bortezomib, exerts broader
effects than the rather specific IKKb inhibitor, KINK-1.
However, whether these broader effects of bortezomib are
generally beneficial or harmful in tumor therapy is not clear
and may depend on the tumor type treated.
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Figure 7. Kinase inhibitor of NF-jB-1 (KINK-1) and bortezomib enhance susceptibility of melanoma cells to camptothecin in vivo. (a) B16F10 melanoma cells
were stably transfected with green fluorescent protein, and C57BL/6 mice were intravenously injected with 2.5105 fluorescent cells per mouse. Cryostat-cut
sections of the lungs of the animals were analyzed by fluorescence microscopy after 5 hours to visualize pulmonary arrest of the tumor cells. The
photomicrograph shown is representative for similar results obtained with three mice. Bar¼50 mm. (b) Pulmonary metastasis was analyzed in C57BL/6 mice
intravenously injected with 2.5 105 B16F10 melanoma cells and intraperitoneally treated with KINK-1, bortezomib, camptothecin, or combinations as
indicated. Doses and treatment regimens were as outlined in the text. (c) Quantitative analysis of the antitumoral responses elicited by the indicated treatment
regimens by two independent objective methods, lung weight as a surrogate parameter of tumor masses (upper panel) and computer-based analysis of
tumor-covered lung surfaces (bottom panel). ***Indicates Po0.001, **indicates Po0.01, and *indicates Po0.05 compared with the effect of camptothecin
alone. Comparison of combination treatments with treatment with the NF-kB inhibitors alone or with controls was always Po0.001.
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Third, some gene products which are affected differently
by proteasome inhibition or by IKKb inhibition may be
regulated redundantly by more than one transcription factor,
thus evading the effect of a compound that specifically targets
only NF-kB activation, such as KINK-1. Examples for such
molecules are the E2F and the hypoxia-inducible factor-1a
(HIF-1a) transcription factors, which are involved in the
regulation of NOXA mRNA under stress (Hershko and
Ginsberg, 2004; Kim et al., 2004). Such gene products
would respond to bortezomib, but not to KINK-1.
Fourth, expression of some NF-kB-regulated proteins
including cyclin D1, survivin, and c-MYC did not correlate
with translocation of p65 to the nucleus, a notion that is not
easy to reconcile with the regulation of these genes by NF-kB.
These observations underscore the complexity in the genetic
response to NF-kB, thereby suggesting that posttranscrip-
tional and posttranslational activation also participate in the
expression of these proteins (Hassa and Hottiger, 1999;
Campbell and Perkins, 2004). Although bortezomib-induced
upregulation of NOXA has been attributed in part to
regulation by c-MYC (Nikiforov et al., 2007), the molecular
mechanisms underlying upregulation of NOXA need to be
clarified in further studies.
Fifth, bortezomib induced a longer-lasting and more
profound cellular arrest as compared with KINK-1. It is,
therefore, conceivable that the longer arrest of the cell cycle
sensitizes bortezomib-treated tumor cells to low doses of
camptothecin. In contrast, KINK-1 showed a less pronounced
effect on the cell cycle, but it antagonized the camptothecin-
induced upregulation of the tumor progression-related
chemokines CCL1 (MCP-1), CXCL1 (Gro-a), and CXCL8
(IL-8) (Denkert et al., 2001; Dhawan and Richmond, 2002;
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Figure 8. Synergistic effect of camptothecin and NF-jB inhibitors in vivo. (a) Pulmonary metastases were analyzed by a modified TUNEL assay in C57BL/6
mice intravenously injected with 2.5 105 B16F10 melanoma cells. Mice were either untreated or intraperitoneally treated with kinase inhibitor of NF-kB-1
(KINK-1), bortezomib, camptothecin, or combinations as indicated. Examples of TUNEL-positive nuclei (blue) are indicated by arrows. (b) Quantitative analysis
of apoptotic cells in pulmonary melanoma metastases in C57BL/6 mice. Mice were treated as outlined in (a) and apoptotic cells were counted in at least five
sections from each condition. The values shown represent the mean apoptotic index (±SD). **Indicates Po0.001. (c) NF-kB was detected by
immunohistochemistry in pulmonary melanoma metastases of untreated mice or mice treated with camptothecin, or a combination of camptothecin and
bortezomib or KINK-1 as indicated. Arrows highlight examples of tumor cells with nuclear detection of NF-kB. Bar¼20 mm.
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Payne and Cornelius, 2002; Eck et al., 2003; Gazzaniga
et al., 2007; Koga et al., 2008) more effectively as compared
with bortezomib. The net effect, however, would be similar
in both cases, that is, synergistic enhancement of the
susceptibility of melanoma cells to antitumoral treatment by
camptothecin.
Finally, NF-kB can be activated in a proteasome-indepen-
dent fashion in some cells (Shumway and Miyamoto, 2004), a
notion that suggests that other strategies of NF-kB inhibition,
such as targeting IKKb, may be more successful in such cells.
Again, further studies are needed to determine whether
melanoma cells possess the capacity to activate NF-kB in
such a manner.
In any case, our results show that similar net effects
achieved by different strategies of NF-kB inhibition, that is,
profound synergistic reduction of melanoma cell invasion
and metastasis when combined with a cytostatic drug, can be
based on distinctly different molecular mechanisms (Figure 8).
This notion may carry therapeutic implications in at least two
ways: on the one hand, it is conceivable that switching NF-
kB-inhibiting agents, once resistance to the first compound
has occurred, will keep the tumor cells susceptible to
antitumoral treatment. On the other hand, one might
consider combining two (or more) NF-kB-inhibiting princi-
ples with distinct molecular modes of action, thus more
effectively preventing the development of chemoresistance
and reducing the risk of unwanted side effects. In addition, as
bortezomib may induce de novo chemoresistance in some
tumors (Chauhan et al., 2004a, b; Kuhn et al., 2007),
combining this drug with another NF-kB-inhibiting drug
may be advantageous. These hypotheses, however, need to
be tested in further studies (Figure 9).
MATERIALS AND METHODS
Cells and culture conditions
Human melanoma lines A 375, Mel-2a, SK-Mel 23, Brown, MeWo,
MMNH, MV3, and Lox and the murine melanoma line B16F10 were
grown in DMEM supplemented with 10% fetal calf serum,
100Uml1 penicillin, and 100mgml1 streptomycin (Gibco,
Karlsruhe, Germany).
Western blot analysis
Protein concentrations in the cytoplasmic, mitochondrial, and
nuclear fractions, as well as in whole cell lysates were determined
by the Bradford assays. Equal amounts of protein were separated by
SDS-PAGE and transferred onto nitrocellulose membranes. Proteins
of interest were detected using mAb followed by peroxidase-labeled
goat anti-mouse IgG or peroxidase-labeled goat anti-rabbit IgG and a
chemiluminescence reaction (ECL, Amersham, Buckinghamshire,
UK). Anti-human Bax (2D2; Biozol, Eching, Germany), anti-human
Bcl-XL (H-5; Santa Cruz Biotechnology, Heidelberg, Germany), anti-
human survivin (D-8; Santa Cruz Biotechnology), anti-human p53
(Pab421, Calbiochem, San Diego, CA), and anti-human c-MYC
(9E10; Santa Cruz Biotechnology) were used at 1:50 dilutions. Anti-
human XIAP (2F1; Biozol), anti-human b-actin (Abcam, Biozol), and
anti-human cyclin D1 (DCS6; Cell Signaling, Danvers, MA) were
used at 1:1,000 dilutions. Anti-human cytochrome C (7H8.2C12;
Becton Dickinson, Heidelberg, Germany), anti-human NOXA
(114C307.1; Imgenex, San Diego, CA), and anti-human Bcl-2 (clone
124; DAKO Cytomation, Hamburg, Germany) were used at 1:500
dilutions.
Electrophoretic mobility shift assays
Subcellular fractionation and preparation of nuclear extracts was
performed as described previously (Scho¨n et al., 2008). Equal
amounts of protein (determined by Bradford assay) from nuclear
extracts (10 mg) of cells treated with KINK-1 (2, 5, 15, or 25 mM),
Bortezomib (2, 5, 10, or 30 ngml1), and tumor necrosis factor-a
(1 nM) were incubated with 32P end-labeled, double stranded NF-kB
oligonucleotide (50-AGTTGAGGGGACTTTCCCAGGC-30) (Gel shift
assay systems; Promega, Madison, WI) for 20minutes at room
temperature. Subsequently, the DNA–protein complexes were
resolved in a 6.6% native polyacrylamide gel. For supershift assays,
nuclear extracts (10 mg) were incubated with antibodies (1mg)
against p65 (F-6), p50 (E-10; both from Santa Cruz Biotechnology)
or a combination of both for 30minutes at 20 1C before analysis by
electrophoretic mobility shift assays. Radioactive signals were
visualized and quantitated using a PhosphorImager and the Image
Quant software (BioRad, Munich, Germany).
Semiquantitative reverse transcription-PCR
RNA from treated or untreated cells was extracted using the Rneasy
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
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instructions. Gene expression was assessed by reverse transcription-
PCR (Oostingh et al., 2007). Primers and reaction conditions are
indicated in Supplementary Table S1.
Quantitative real-time PCR
cDNA was prepared from RNA of cells that were treated with either
vehicle or with KINK-1, bortezomib, camptothecin, or combinations
indicated in the text for 18 hours. PCR was performed according to
the manual using the Quanti Tect Primer Assays (Qiagen) for human
CXCL1, CXCL8, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Each PCR was carried out in triplicate in a 25 ml volume
using Quanti Tect SYBR Green Kits (Qiagen) for 5minutes at 95 1C
for initial denaturing, followed by 40 cycles of 95 1C for 10 seconds,
and 60 1C for 30 seconds in the ABI Prism 7000 Sequence detection
system. Values for each gene were normalized to the expression of
GAPDH. Experiments were repeated twice.
Proliferation assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS)-assay)
Cells were plated at a density of 3,000 cells per well in a 96-well
plate. Subconfluent cultures were treated with KINK-1, bortezomib,
camptothecin, or combinations thereof as indicated in the text in a
final volume of 100ml. After 24 or 48 hours, the Cell Titer 96 Aqueous
One Solution Cell Proliferation Assay (Promega, Mannheim,
Germany) was used as described in the manual to measure
proliferation of the cells.
Apoptosis detection (DNA fragmentation assay)
To assess apoptotic responses, cultured cells were incubated with
apoptotic stimuli for 16 hours, lyzed and, by centrifugation at
10,000 g for 10minutes, a clear supernatant was prepared. Equal
amounts were added to microtiter plates coated with anti-histone
antibodies, and incubated for 90minutes at 20 1C. Histone-bound
DNA fragments were detected using the Cell Death Detection ELISA
according to the manual (Roche Diagnostics, Penzberg, Germany).
The substrate reaction, resulting in a green color, was quantitated
using an ELISA reader at 405 nm.
Thymidine treatment for G1/S-phase synchronization and cell
cycle analysis
Subconfluent cell cultures were incubated with 2mM thymidine for
16 hours, washed thrice with phosphate-buffered saline (PBS), and
grown in DMEM containing 0.5% fetal calf serum for 10 hours.
Thereafter, 2mM thymidine was added for 14 hours. Cells were
washed again thrice with PBS and then released with 10% fetal calf
serum-containing medium (a treatment that initiates the cell cycle,
thus ‘‘synchronizing’’ the cells) for 4 or 12hours. Thymidine-treated
cells as well as non-synchronized cells received either DMSO (0.1%,
control), bortezomib (5 or 10ngml1), or KINK-1 (5 or 15mM). For cell
cycle analysis, the fixed cells (70% ethanol on ice) were washed thrice
and resuspended in cold PBS containing 5mgml1 propidium iodide
and 0.1mgml1 RNase A. Flow cytometry was performed using a
FACS Calibur and the CellQuest software (BD, Heidelberg, Germany).
In vitro invasion assay
The invasiveness of melanoma cells was assayed in membrane
invasion culture system by plating the cells on top of a matrigel-
coated, fluorescence-blocking polycarbonate membrane with 8 mm
pores (BD BioCoat Tumor Invasion System; Becton Dickinson).
Melanoma cells were treated with bortezomib (5 ngml1), KINK-1
(5mM), camptothecin (0.03 mM), or combinations thereof for 16 hours,
harvested by trypsin, and washed thrice with DMEM. Thereafter, the
cells were seeded at a density of 5 104 cells per 500 ml DMEM on
the matrigel-coated membrane in the upper compartment. The lower
compartment was filled with 750 ml DMEM containing 10% fetal calf
serum as a chemoattractant, and the plates were incubated at 37 1C
for 24 hours. At the end of the incubation time, the insert plate was
transferred into a second 24-well plate containing 0.5ml per well of
4mgml1 Calcein acetoxymethylester (Molecular Probes, Carlsbad,
CA) in PBS (Gibco) and incubated for 1 hour at 37 1C to stain cells
that invaded through the Matrigel. Finally, the fluorescence-labeled
cells were quantitated using a fluorescence microscope (Axiovert
200, Zeiss, Go¨ttingen, Germany).
Experimental pulmonary metastasis
Mouse experiments were approved by the appropriate authorities
(Regierung von Unterfranken, Wu¨rzburg, Germany). Mice were
housed in a climate-controlled specific pathogen-free facility and, at
the time of termination of the experiment, were killed by ether
anesthesia followed by cervical dislocation according to the
institutional guidelines. C57BL/6 mice (n¼ 6 animals per group)
were injected into the tail vein with 2.5 105 B16F10 murine
melanoma cells. Treatment was started 1 day after melanoma cell
injection. Treatment regimens were as follows: group 1—control: no
treatment; group 2—KINK-1: 3mg kg1 every other day; group
3—bortezomib: 0.5mg kg1 on days 1 and 6, 0.25mg kg1 on day
11; group 4—camptothecin: 1.8mg kg1 on days 2, 5, 7, 10, 13, and
15; group 5—camptothecin and KINK-1: combination of both
compounds using the same regimens as in the respective mono-
therapy groups; group 6—bortezomib and camptothecin: combina-
tion of both compounds using the same regimens as in the respective
monotherapy groups. Metastasis was evaluated at day 17 after
melanoma cell injection. Camptothecin was dissolved in PBS pH 7.4
containing 0.3% sodium carboxymethylcellulose and 0.2% Tween
80 as described (Dora et al., 2006). All animal experiments were
performed independently twice.
Apoptosis detection in pulmonary metastases by TUNEL assays
To prevent the loss of low-molecular-weight DNA fragments, lung
specimens fixed in 4% paraformaldehyde were used for apoptosis
detection. Paraffin-embedded sections were subjected to a modified
TUNEL technique (DermaTACS) according to the manufacturer’s
recommendations (R&D Systems, Wiesbaden, Germany). In this assay,
apoptotic cells are visualized by TACS Blue Label (R&D Systems) as
blue nuclear staining in cells with DNA fragmentation. One section
from each tissue block was incubated with TACS nuclease in order to
generate DNA fragmentation in all cells (positive control). In another
section, TdT was omitted (negative control). Apoptotic cells were
quantitated microscopically in at least five metastases from each
condition in a blinded fashion, and the apoptotic index was calculated
as percentage of TUNEL-positive cells.
GFP transfection and short-term melanoma metastasis
B16F10 melanoma cells were stably transfected with GFP according
to an optimized protocol for B16F10 using 1.5 106 cells, 2mg of
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pmaxGFP, and 100 ml of Nucleofactor solution V (Amaxa, Cologne,
Germany). Transfected cells with high expression of GFP were sorted
by flow cytometry, subcloned thrice, and cultured in DMEM
medium (Gibco) containing 1mgml1 of the G418 selection
supplement (Sigma, Deisenhofen, Germany). GFP-expressing
B16F10 melanoma cells (2.5 105) were injected into the tail vein
of C57BL/6 mice (n¼ 3 animals per group) and killed after 5 hours to
verify that pulmonary cell arrest had occurred before initiating
antitumoral treatment. Cryostat-cut sections of the lung were
assessed microscopically (Zeiss Axioskop). Overlays of phase
contrast and fluorescence microscopy allowed precise topographic
analysis of the tumor cells within the lung tissue.
Statistical analyses
Data are displayed as mean±SD; P-values were determined using
the two-tailed t-test and P-values o0.05 (confidence interval of
95%) were considered statistically significant. All statistical tests
were two-sided.
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